Axsome Therapeutics, Inc.
AXSM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001579428
In the last 90 days, Axsome Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 508 institutions reported holding it in 13F filings for Q2 2026, worth $9.34B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 3, 2026, 1:12 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $183.2M (28.7% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 4, 2024 | Feb 27, 2023 | Mar 1, 2022 |
| Revenue | $638.5M | $385.7M | $270.6M | $0 | – |
| Cost of revenue | – | – | – | $5.20M | – |
| Operating expenses | – | – | – | – | $124.7M |
| Research and development | $183.3M | $187.1M | $97.9M | $57.9M | $58.1M |
| Selling, general and administrative | $570.6M | $411.4M | $323.1M | $159.3M | $66.6M |
| Operating income | -$166.8M | -$280.6M | -$231.8M | -$179.8M | -$124.7M |
| Interest expense | -$15.9M | -$21.6M | – | – | – |
| Income tax | -$530.0K | $85.0K | $960.0K | $0 | $0 |
| Net income | -$183.2M | -$287.2M | -$239.2M | -$187.1M | -$130.4M |
| EPS, basic | $-3.68 | $-5.99 | $-5.27 | $-4.60 | – |
| EPS, diluted | $-3.68 | $-5.99 | $-5.27 | $-4.60 | – |
| Weighted shares, basic | 49.7M | 47.9M | 45.4M | 40.7M | – |
| Weighted shares, diluted | 49.7M | 47.9M | 45.4M | 40.7M | – |
| Margins and growth | |||||
| Operating margin | -26.1% | -72.7% | -85.7% | – | – |
| Net margin | -28.7% | -74.5% | -88.4% | – | – |
| Revenue growth, year over year | +65.5% | +42.5% | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 4, 2024 | Feb 27, 2023 | Mar 1, 2022 |
| Cash and equivalents | $322.9M | $315.4M | $386.2M | $200.8M | $86.5M |
| Accounts receivable | $224.5M | $142.0M | $94.8M | $37.7M | – |
| Inventory | $27.9M | $15.7M | $15.1M | $4.32M | – |
| Total current assets | $589.0M | $485.1M | $504.3M | $245.6M | $86.5M |
| Property, plant and equipment | $562.0K | $584.0K | $846.0K | $722.5K | $283.8K |
| Goodwill | $12.0M | $12.0M | $12.0M | $10.3M | – |
| Intangible assets | $40.5M | $46.9M | $53.3M | $59.7M | – |
| Total assets | $689.8M | $568.5M | $588.2M | $331.5M | $87.8M |
| Accounts payable | $65.5M | $72.0M | $40.7M | $38.6M | $13.1M |
| Short-term debt | $70.0M | – | – | – | – |
| Total current liabilities | $378.8M | $230.1M | $138.9M | $96.6M | $23.1M |
| Long-term debt | $117.7M | $180.7M | $178.1M | $94.3M | $49.1M |
| Total liabilities | $601.5M | $511.5M | $397.3M | $221.9M | $72.2M |
| Shareholders' equity | $88.3M | $57.0M | $191.0M | $109.6M | $15.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 4, 2024 | Feb 27, 2023 | Mar 1, 2022 |
| Operating cash flow | -$93.4M | -$128.4M | -$145.1M | -$116.5M | -$108.2M |
| Capital expenditures | $480.0K | $270.0K | $582.0K | $702.1K | $307.5K |
| Free cash flow | -$93.9M | -$128.7M | -$145.7M | -$117.2M | -$108.5M |
| Stock-based compensation | $93.8M | $85.2M | $62.6M | $37.7M | $20.8M |
| Investing cash flow | -$480.0K | -$270.0K | -$582.0K | -$53.7M | -$307.5K |
| Financing cash flow | $101.5M | $57.8M | $331.0M | $284.6M | $11.1M |
| Net change in cash | $7.58M | -$70.8M | $185.4M | $114.4M | -$97.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 14.7% | 22.1% | 23.1% | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 26, 2026 | 52.6M | +4.3% | SEC |
| Aug 3, 2026 | 52.4M | +5.0% | SEC |
| Apr 27, 2026 | 51.5M | +4.5% | SEC |
| Feb 16, 2026 | 51.2M | +4.9% | SEC |
| Oct 27, 2025 | 50.4M | +4.0% | SEC |
| Jul 28, 2025 | 49.9M | +4.0% | SEC |
| Apr 28, 2025 | 49.2M | +3.7% | SEC |
| Feb 11, 2025 | 48.8M | +2.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.